Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Colorectal Neoplasms

Free Subscription Articles published in Int J Oncol Retrieve available abstracts of 27 articles: HTML format

Single Articles

May 2023
1. CUI K, Wu H, Zhang L, Li H, et al
   A novel lncRNA 495810 promotes the aerobic glycolysis in colorectal cancer by stabilizing pyruvate kinase isozyme M2.
   Int J Oncol. 2023;62:58.
   PubMed     Abstract available
   
   
   April 2023
2. OH HH, Park YL, Park SY, Joo YE, et al
   A disintegrin and metalloprotease 12 contributes to colorectal cancer metastasis by regulating epithelial‑mesenchymal transition.
   Int J Oncol. 2023;62:50.
   PubMed     Abstract available
   
   
   March 2023
3. CHEN J, Xu J, Yang J, Zhan Y, et al
   alpha‑hederin overcomes hypoxia‑mediated drug resistance in colorectal cancer by inhibiting the AKT/Bcl2 pathway.
   Int J Oncol. 2023;62:33.
   PubMed     Abstract available
   
   
   
4. LIU P, Liu J, Ding M, Liu Y, et al
   FUT2 promotes the tumorigenicity and metastasis of colorectal cancer cells via the Wnt/beta‑catenin pathway.
   Int J Oncol. 2023;62:35.
   PubMed     Abstract available
   
   
   February 2023
5. CHEN Y, Chen M, Deng K
   Blocking the Wnt/beta‑catenin signaling pathway to treat colorectal cancer: Strategies to improve current therapies (Review).
   Int J Oncol. 2023;62:24.
   PubMed     Abstract available
   
   
   January 2023
6. SUI L, Zeng J, Zhao H, Ye L, et al
   Death associated protein3 (DAP3) and DAP3 binding cell death enhancer1 (DELE1) in human colorectal cancer, and their impacts on clinical outcome and chemoresistance.
   Int J Oncol. 2023;62.
   PubMed     Abstract available
   
   
   
7. LEE YJ, Jung E, Choi J, Hwang JS, et al
   The EDN1/EDNRA/beta‑arrestin axis promotes colorectal cancer progression by regulating STAT3 phosphorylation.
   Int J Oncol. 2023;62:13.
   PubMed     Abstract available
   
   
   December 2022
8. RAO X, Lin L
   Circadian clock as a possible control point in colorectal cancer progression (Review).
   Int J Oncol. 2022;61.
   PubMed     Abstract available
   
   
   November 2022
9. PAUL S, Bhardwaj M, Kang SC
   GSTO1 confers drug resistance in HCT116 colon cancer cells through an interaction with TNFalphaIP3/A20.
   Int J Oncol. 2022;61.
   PubMed     Abstract available
   
   
   October 2022
10. DENG Y, Fu H, Han X, Li Y, et al
    Activation of DDX58/RIGI suppresses the growth of tumor cells by inhibiting STAT3/CSE signaling in colon cancer.
    Int J Oncol. 2022;61.
    PubMed     Abstract available
    
    
    September 2022
11. LI M, Xia M, Zhang Z, Tan Y, et al
    METTL3 antagonizes 5FU chemotherapy and confers drug resistance in colorectal carcinoma.
    Int J Oncol. 2022;61.
    PubMed     Abstract available
    
    
    
12. TERADO T, Kim CJ, Ushio A, Minami K, et al
    Cryptotanshinone suppresses tumorigenesis by inhibiting lipogenesis and promoting reactive oxygen species production in KRASactivated pancreatic cancer cells.
    Int J Oncol. 2022;61.
    PubMed     Abstract available
    
    
    June 2022
13. CHANG CC, Kao WY, Liu CY, Su HH, et al
    Butyrate supplementation regulates expression of chromosome segregation 1like protein to reverse the genetic distortion caused by p53 mutations in colorectal cancer.
    Int J Oncol. 2022;60.
    PubMed     Abstract available
    
    
    
14. CITRIN D, Valle L, Camphausen K, Cooley-Zgela T, et al
    Pilot trial of topical MTS01 application to reduce dermatitis in patients receiving chemoradiotherapy for stage IIII carcinoma of the anal canal.
    Int J Oncol. 2022;60.
    PubMed     Abstract available
    
    
    
15. ZHAO Q, Long Y, Cheng W, Huang Y, et al
    Visfatin inhibits colon cancer cell apoptosis and decreases chemosensitivity to 5FU by promoting the SDF1/CXCR4/Akt axis.
    Int J Oncol. 2022;60.
    PubMed     Abstract available
    
    
    
16. BRUNO G, Li Bergolis V, Piscazzi A, Crispo F, et al
    TRAP1 regulates the response of colorectal cancer cells to hypoxia and inhibits ribosome biogenesis under conditions of oxygen deprivation.
    Int J Oncol. 2022;60.
    PubMed     Abstract available
    
    
    March 2022
17. ABDULLA M, Traiki TB, Vaali-Mohammed MA, El-Wetidy MS, et al
    Targeting MUCL1 protein inhibits cell proliferation and EMT by deregulating betacatenin and increases irinotecan sensitivity in colorectal cancer.
    Int J Oncol. 2022;60.
    PubMed     Abstract available
    
    
    February 2022
18. WANG J, Yokoyama Y, Hirose H, Shimomura Y, et al
    Functional assessment of miR1291 in colon cancer cells.
    Int J Oncol. 2022;60.
    PubMed     Abstract available
    
    
    
19. CHEN S, Nishi M, Morine Y, Shimada M, et al
    Epigallocatechin3gallate hinders metabolic coupling to suppress colorectal cancer malignancy through targeting aerobic glycolysis in cancerassociated fibroblasts.
    Int J Oncol. 2022;60.
    PubMed     Abstract available
    
    
    
20. BAHR I, Jaeschke L, Nimptsch K, Janke J, et al
    Obesity, colorectal cancer and MACC1 expression: A possible novel molecular association.
    Int J Oncol. 2022;60.
    PubMed     Abstract available
    
    
    
21. PAN S, Deng Y, Fu J, Zhang Y, et al
    N6methyladenosine upregulates miR181d5p in exosomes derived from cancerassociated fibroblasts to inhibit 5FU sensitivity by targeting NCALD in colorectal cancer.
    Int J Oncol. 2022;60.
    PubMed     Abstract available
    
    
    January 2022
22. LIAO Z, Zhang H, Fan P, Huang Q, et al
    [Corrigendum] High PLK4 expression promotes tumor progression and induces epithelialmesenchymal transition by regulating the Wnt/betacatenin signaling pathway in colorectal cancer.
    Int J Oncol. 2022;60.
    PubMed     Abstract available
    
    
    
23. WATANABE K, Shiga K, Maeda A, Harata S, et al
    Chitinase 3-like 1 secreted from cancer-associated fibroblasts promotes tumor angiogenesis via interleukin-8 secretion in colorectal cancer.
    Int J Oncol. 2022;60.
    PubMed     Abstract available
    
    
    December 2021
24. SHI W, Men L, Pi X, Jiang T, et al
    Shikonin suppresses colon cancer cell growth and exerts synergistic effects by regulating ADAM17 and the IL6/STAT3 signaling pathway.
    Int J Oncol. 2021;59.
    PubMed     Abstract available
    
    
    March 2021
25. HA THI HT, Duong HQ, Hong S
    Emerging roles of noncoding RNAs in the response of rectal cancer to radiotherapy (Review).
    Int J Oncol. 2021;58:344-358.
    PubMed     Abstract available
    
    
    February 2021
26. ANDO S, Fukamachi K, Yoshimoto E, Matsumoto H, et al
    Palmitoyl piperidinopiperidine, a novel derivative of 10hydroxy2decenoic acid, as a potent and selective anticancer agent against human colon carcinoma cell lines.
    Int J Oncol. 2021;58:251-265.
    PubMed     Abstract available
    
    
    September 2020
27. FENG J, Xiao T, Lu SS, Hung XP, et al
    ANXA1derived peptides suppress gastric and colon cancer cell growth by targeting EphA2 degradation.
    Int J Oncol. 2020 Sep 7. doi: 10.3892/ijo.2020.5119.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: